Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. 1997

R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
Division of Circulatory Physiology, Columbia University, College of Physicians and Surgeons, New York, New York, USA.

To determine the effect of beta blockade on parasympathetic nervous system activity, we assessed RR variability during 24-hour Holter monitoring in 10 patients with congestive heart failure before and after 3 to 4 months of treatment with the beta blocker carvedilol. High-frequency power increased from 26 to 64 ms2, root-mean-square of successive differences in RR interval increased from 14.3 to 23.7 ms2, and percentage of absolute differences >50 ms between successive normal RR intervals increased from 0.8% to 4.7%, all p <0.01, indicating a substantial increase in parasympathetic modulation of RR intervals.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010275 Parasympathetic Nervous System The craniosacral division of the autonomic nervous system. The cell bodies of the parasympathetic preganglionic fibers are in brain stem nuclei and in the sacral spinal cord. They synapse in cranial autonomic ganglia or in terminal ganglia near target organs. The parasympathetic nervous system generally acts to conserve resources and restore homeostasis, often with effects reciprocal to the sympathetic nervous system. Nervous System, Parasympathetic,Nervous Systems, Parasympathetic,Parasympathetic Nervous Systems,System, Parasympathetic Nervous,Systems, Parasympathetic Nervous
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure

Related Publications

R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
May 1984, The American journal of cardiology,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
June 2004, Expert opinion on pharmacotherapy,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
January 1980, Cardiology,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
November 1987, Klinische Wochenschrift,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
June 1986, The Journal of the Association of Physicians of India,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
March 1985, Kokyu to junkan. Respiration & circulation,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
May 2006, Journal of cardiology,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
July 1992, Clinical pharmacy,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
January 1989, Journal of cardiovascular pharmacology,
R L Goldsmith, and J T Bigger, and D M Bloomfield, and H Krum, and R C Steinman, and J Sackner-Bernstein, and M Packer
April 1957, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!